Description
Tilorone (Flogardin) Pharmacodynamics
Low-molecular synthetic inducer of interferon, stimulating the formation of all types of interferon in the body (alpha, beta, gamma and lambda). The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours.
Tilorone has immunomodulatory and antiviral effects.
According to experimental data, after a single oral administration of Tilorone at a dose equivalent to the maximum daily dose for humans, the maximum concentration in the lung tissue of interferon lambda is determined after 24 hours, interferon alpha – after 48 hours. Induction of interferon lambda in the lung tissue enhances antiviral protection of the respiratory tract during influenza and other respiratory viral infections. In human leukocytes, tiloron induces interferon synthesis. It stimulates bone marrow stem cells, and, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors to T-helpers.
Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppression of virus reproduction.
Indications
As part of the complex therapy for children from 7 to 18 years:
– Treatment of influenza and other acute respiratory viral infections (ARI).
Contraindications
- Hypersensitivity to Tyloron or other components of the drug; pregnancy and lactation; children under 7 years of age.
- Usage during pregnancy and breastfeeding
- The use of Flogardin during pregnancy is contraindicated.
- If it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued.
Dosage and administration
- Oral administration, after a meal.
- In case of uncomplicated forms of influenza and acute respiratory viral infections, 60 mg per day on days 1, 2 and 4 from the start of treatment. The course dose is 180 mg (3 tablets per course of treatment).
- During treatment of influenza and other acute respiratory viral infections, in case of preservation of symptoms for more than 4 days, you should consult your doctor.